Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Limited) has disclosed an upcoming virtual one-on-one meeting with Karma Capital, an institutional investor, scheduled for May 22, 2026. This disclosure is made under SEBI's Regulation 30, which requires companies to inform stock exchanges about analyst or investor meetings. The company has clarified that the schedule may change due to unforeseen circumstances. This is a routine regulatory filing to maintain transparency about institutional investor interactions.
This is a standard procedural disclosure and does not indicate any material corporate development or financial update. It shows the company remains engaged with institutional investors but carries no direct implications for the stock price.